Current and new antitumor necrosis factor agents in perspective

Arthritis Research and Therapy

Volumn 6, Issue SUPPL. 2, 2004, Pages

  Maini, Ravinder N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LABORATORY TEST; PAIN ASSESSMENT; POSTMARKETING SURVEILLANCE; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

EID: 21644472540     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar994     Document Type: Review

References (17)

1. Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997, 18:487-492.
2. Punzi L, Calo L, Plebani M: Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci 2002, 39:63-88.
3. Feldmann M, Brennan FM, Maini RN: Role of cylokines in rheumatoid arthritis. Annu Rev Immunol 1996,14:397-440.
4. Feldmann M, Maini RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001, 19: 163-196.
5. Brennan FM, Maini RN, Feldmann M: TNF alpha - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992, 31:293-298.
6. Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res 2002, 4(Suppl 2): S22-S28.
7. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum 1993, 36: 1681-1690.
8. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
9. Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet 2001, 358: 903-911.
10. Medical Economics Company Inc: Prescribing information: Enbrel®. In Physicians' Desk Reference®. Montvale, NJ; 2002:3504-3507.
11. Centocor, Inc.: Remicade: Package insert, revised June 2002. Malvern, PA; 2002.
12. Abbott Laboratories: Humira: Package insert. Abbott Park, IL; 2002.
13. Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001, 28:1423-1430.
14. Kremer JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001, 134: 695-706.
15. Geborek P, Crnkic M, Teleman A: Tolerability using survival on drug as evaluation tool. Experience of etanercept, infliximab and lefluonomide in rheumatoid arthritis (RA) [abstract]. Presented at the American College of Rheumatology 65th Annual Scientific Meeting/Association of Rheumatology Health Professionals 36th Annual Scientific Meeting; November 10-15, 2001; San Francisco, CA.
16. American College of Rheumatology: FDA advisory committee reviews safety of TNF inhibitors [www.rheumatology.org/ research/hotline/0901tnf.html]. Accessed 22 April 2002.
17. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.